Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Increase in Short Interest

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,800 shares, an increase of 1,300.0% from the October 31st total of 200 shares. Based on an average daily volume of 5,400 shares, the short-interest ratio is presently 0.5 days.

Clinuvel Pharmaceuticals Stock Performance

Shares of CLVLY opened at $8.50 on Thursday. The firm’s fifty day simple moving average is $9.33 and its 200-day simple moving average is $9.67. Clinuvel Pharmaceuticals has a twelve month low of $8.00 and a twelve month high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The firm also recently declared a dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a $0.0299 dividend. The ex-dividend date of this dividend was Monday, September 9th. This is a boost from Clinuvel Pharmaceuticals’s previous dividend of $0.03.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).